Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 70

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 8
Chunk 70
---
 cash and restricted cash 
    $(617) 
    $(6,560)

NET CASH USED IN OPERATING ACTIVITIES. We used
cash in our operating activities due to our losses from operations. Net cash used in operating activities was approximately $5,973,000
in the nine months ended December 31, 2024, compared to approximately $7,564,000 in the nine months ended December 31, 2023. The primary
components in the $1,591,000 decrease in cash used in our operating activities in the 2024 period was a decrease in our net loss of approximately
$2,649,000 partially offset by a negative net change in other working capital components of $508,000 and the reduction of $550,000 in
non-cash components.

NET CASH USED IN INVESTING ACTIVITIES. We used
approximately $2,000 for investing activities in the nine months ended December 31, 2024, compared to approximately $245,000 in the nine
months ended December 31, 2023. The $243,000 decrease in the 2024 period was primarily a result of equipment purchase for our laboratory
incurred in the nine months ended December 2023.

NET CASH PROVIDED BY FINANCING ACTIVITIES. During
the nine months ended December 31, 2024, we raised approximately $5,384,000, net of placement agent fees and offering costs, from the
sale and issuance of our common stock and warrants in connection with a public offering and the exercise of 300,000 and 2,880,000 Class
A and Class B warrants, respectively, by holders thereof. The source of cash from our financing activities was partially offset by the
use of approximately $16,000 to pay for the tax withholding upon settlement of on restricted stock units, for a net aggregate amount of
cash provided by financing activities of approximately $5,368,000.

During the nine months ended December 31, 2023,
we raised approximately $1,273,000 from the issuance of our common stock under our at the market facility. That source of cash from our
financing activities was partially offset by the use of approximately $28,000 to pay for the tax withholding on restricted stock units,
for a net aggregate amount of cash provided by financing activities of approximately $1,245,000.

Material Cash Requirements 

We expect our clinical trial expenses for our
oncology trials